Suzhou Zelgen Biopharmaceuticals (SHA:688266) will conduct clinical trials on a combination of two drugs after obtaining approval from the Chinese drug administration, according to a Shanghai Stock Exchange disclosure on Thursday.
The biopharmaceutical company will trial ZG005 injection combined with gecaxitinib hydrochloride tablets as a treatment for advanced solid tumors and relapsed and refractory lymphoma.
The company's shares closed over 1% higher.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments